Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19
Carlo Cervia, Jakob Nilsson, Yves Zurbuchen, Alan Valaperti, Jens Schreiner, Aline Wolfensberger, Miro E Raeber, Sarah Adamo, Sebastian Weigang, Marc Emmenegger, Sara Hasler, Philipp P Bosshard, Elena De Cecco, Esther Bächli, Alain Rudiger, Melina Stüssi-Helbling, Lars C Huber, Annelies S Zinkernagel, Dominik J Schaer, Adriano Aguzzi, Georg Kochs, Ulrike Held, Elsbeth Probst-Müller, Silvana K Rampini, Onur Boyman, Carlo Cervia, Jakob Nilsson, Yves Zurbuchen, Alan Valaperti, Jens Schreiner, Aline Wolfensberger, Miro E Raeber, Sarah Adamo, Sebastian Weigang, Marc Emmenegger, Sara Hasler, Philipp P Bosshard, Elena De Cecco, Esther Bächli, Alain Rudiger, Melina Stüssi-Helbling, Lars C Huber, Annelies S Zinkernagel, Dominik J Schaer, Adriano Aguzzi, Georg Kochs, Ulrike Held, Elsbeth Probst-Müller, Silvana K Rampini, Onur Boyman
Abstract
Background: Whereas severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibody tests are increasingly being used to estimate the prevalence of SARS-CoV-2 infection, the determinants of these antibody responses remain unclear.
Objectives: Our aim was to evaluate systemic and mucosal antibody responses toward SARS-CoV-2 in mild versus severe coronavirus disease 2019 (COVID-19) cases.
Methods: Using immunoassays specific for SARS-CoV-2 spike proteins, we determined SARS-CoV-2-specific IgA and IgG in sera and mucosal fluids of 2 cohorts, including SARS-CoV-2 PCR-positive patients (n = 64) and PCR-positive and PCR-negtive health care workers (n = 109).
Results: SARS-CoV-2-specific serum IgA titers in patients with mild COVID-19 were often transiently positive, whereas serum IgG titers remained negative or became positive 12 to 14 days after symptom onset. Conversely, patients with severe COVID-19 showed a highly significant increase of SARS-CoV-2-specific serum IgA and IgG titers after symptom onset. Very high titers of SARS-CoV-2-specific serum IgA were correlated with severe acute respiratory distress syndrome. Interestingly, some health care workers with negative SARS-CoV-2-specific serum antibody titers showed SARS-CoV-2-specific IgA in mucosal fluids with virus-neutralizing capacity in some cases. SARS-CoV-2-specific IgA titers in nasal fluids were inversely correlated with age.
Conclusions: Systemic antibody production against SARS-CoV-2 develops mainly in patients with severe COVID-19, with very high IgA titers seen in patients with severe acute respiratory distress syndrome, whereas mild disease may be associated with transient production of SARS-CoV-2-specific antibodies but may stimulate mucosal SARS-CoV-2-specific IgA secretion.
Keywords: COVID-19; COVID-19 seroprevalence; COVID-19 severity; SARS-CoV-2; SARS-CoV-2–specific IgA; SARS-CoV-2–specific IgG; SARS-CoV-2–specific antibodies; humoral immune response; mucosal immune response.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Figures
References
- Coronaviridae Study Group of the International Committee on Taxonomy of Viruses The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5:536–544.
- Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–269.
- Zhou P., Yang X.-L., Wang X.-G., Hu B., Zhang L., Zhang W., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273.
- Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–733.
- Dong E., Du H., Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20:533–534.
- V’kovski P, Gultom M, Steiner S, Kelly J, Russeil J, Mangeat B, et al. Disparate temperature-dependent virus – host dynamics for SARS-CoV-2 and SARS-CoV in the human respiratory epithelium [e-pub ahead of print]. bioRxiv . Accessed November 27, 2020.
- Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility [e-pub ahead of print]. N Engl J Med . Accessed November 27, 2020.
- Tong Z.-D., Tang A., Li K.-F., Li P., Wang H.-L., Yi J.-P., et al. Potential presymptomatic transmission of SARS-CoV-2, Zhejiang Province, China, 2020. Emerg Infect Dis. 2020;26:1052–1054.
- Li R., Pei S., Chen B., Song Y., Zhang T., Yang W., et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2) Science. 2020;368:489–493.
- Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239.
- Zhang J., Dong X., Cao Y., Yuan Y., Yang Y., Yan Y., et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75:1730–1741.
- Yang X., Yu Y., Xu J., Shu H., Xia J., Liu H., et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8:475–481.
- ARDS Definition Task Force. Ranieri V.M., Rubenfeld G.D., Thompson B.T., Ferguson N.D., Caldwell E., et al. Acute respiratory distress syndrome: the Berlin definition. JAMA. 2012;307:2526–2533.
- WHO Clinical management of severe acute respiratory infection when COVID-19 is suspected [e-pub ahead of print] Available at: Accessed November 27, 2020.
- Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.-L., Abiona O., et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–1263.
- To K.K.-W., Tsang O.T.-Y., Leung W.-S., Tam A.R., Wu T.-C., Lung D.C., et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20:565–574.
- Ni L., Ye F., Cheng M.-L., Feng Y., Deng Y.-Q., Zhao H., et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020;52:971–977.e3.
- Schulz K.S., Mossman K.L. Viral evasion strategies in type I IFN signaling - a summary of recent developments. Front Immunol. 2016;7:498.
- Hu Y., Li W., Gao T., Cui Y., Jin Y., Li P., et al. The severe acute respiratory syndrome coronavirus nucleocapsid inhibits type I interferon production by interfering with TRIM25-mediated RIG-I ubiquitination. J Virol. 2017;91
- Blanco-Melo D., Nilsson-Payant B.E., Liu W.-C., Uhl S., Hoagland D., Møller R., et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181:1036–1045.e9.
- Amanna I.J., Slifka M.K. Mechanisms that determine plasma cell lifespan and the duration of humoral immunity: long-term antibody production. Immunol Rev. 2010;236:125–138.
- Azkur A.K., Akdis M., Azkur D., Sokolowska M., Veen W., Brüggen M., et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy. 2020;75:1564–1581.
- Callow K.A., Parry H.F., Sergeant M., Tyrrell D.A.J. The time course of the immune response to experimental coronavirus infection of man. Epidemiol Infect. 1990;105:435–446.
- Bryant J.E., Azman A.S., Ferrari M.J., Arnold B.F., Boni M.F., Boum Yap, et al. Serology for SARS-CoV-2: apprehensions, opportunities, and the path forward. Sci Immunol. 2020;5
- Hoffmann M., Kleine-Weber H., Schroeder S., Krüger N., Herrler T., Erichsen S., et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–280.e8.
- Ou X., Liu Y., Lei X., Li P., Mi D., Ren L., et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11:1620.
- Swissnoso Recommendations for healthcare workers, having had unprotected close contact with COVID-19 cases. Available at:
- Kaegi C., Wuest B., Schreiner J., Steiner U.C., Vultaggio A., Matucci A., et al. Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders. Front Immunol. 2019;10:1990.
- Meyer B., Torriani G., Yerly S., Mazza L., Calame A., Arm-Vernez I., et al. Validation of a commercially available SARS-CoV-2 serological immunoassay. Clin Microbiol Infect. 2020;26:1386–1394.
- Emmenegger M, De Cecco E, Lamparter D, Jacquat RPB, Ebner D, Schneider MM, et al. Early peak and rapid decline of SARS-CoV-2 seroprevalence in a Swiss metropolitan region [e-pub ahead of print]. medRxiv Available at: . Accessed November 27, 2020.
- Hollander M., Wolfe D.A. 2nd ed. John Wiley & Sons; Hoboken, NJ: 1999. Nonparametric statistical methods.
- Thissen D., Steinberg L., Kuang D. Quick and easy implementation of the Benjamini-Hochberg procedure for controlling the false positive rate in multiple comparisons. J Educ Behav Stat. 2002;27:77–83.
- Liu Y., Yan L.-M., Wan L., Xiang T.-X., Le A., Liu J.-M., et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis. 2020;20:656–657.
- Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062.
- Brodin P., Davis M.M. Human immune system variation. Nat Rev Immunol. 2017;17:21–29.
- Chan C.M., Tse H., Wong S.S.Y., Woo P.C.Y., Lau S.K.P., Chen L., et al. Examination of seroprevalence of coronavirus HKU1 infection with S protein-based ELISA and neutralization assay against viral spike pseudotyped virus. J Clin Virol. 2009;45:54–60.
- van Deursen J.M. The role of senescent cells in ageing. Nature. 2014;509:439–446.
- Goronzy J.J., Weyand C.M. Successful and maladaptive T cell aging. Immunity. 2017;46:364–378.
- Ng K.W., Faulkner N., Cornish G.H., Rosa A., Harvey R., Hussain S., et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020 eabe1107.
- Liu L., Wei Q., Lin Q., Fang J., Wang H., Kwok H., et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight. 2019;4
- Tay M.Z., Poh C.M., Rénia L., MacAry P.A., Ng L.F.P. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20:363–374.
- Yu H., Sun B., Fang Z., Zhao J., Liu X., Li Y., et al. Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients. Eur Respir J. 2020;56
- Shen C., Wang Z., Zhao F., Yang Y., Li J., Yuan J., et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323:1582.
- Chevrier S, Zurbuchen Y, Cervia C, Adamo S, Raeber ME, de Souza N, et al. A distinct innate immune signature marks progression from mild to severe COVID-19 [e-pub ahead of print]. bioRxiv Available at: . Accessed November 27, 2020.
- Adamo S, Chevrier S, Cervia C, Zurbuchen Y, Raeber ME, Yang L, et al. Lymphopenia-induced T cell proliferation is a hallmark of severe COVID-19 [e-pub ahead of print]. bioRxiv Available at: . Accessed November 27, 2020.
Source: PubMed